Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2024-01-05 14:30:17 ET More on the markets SPY And QQQ: Fundamentals Remain Strong, Buying The Dip Verily Volatility: SPY Puts Are Cheap And The Market Is Selling Off The Market Looks Poised To Make New Highs In 2024 ETFs attract $597B in 2023 marking the fou...
2023-12-31 01:55:00 ET Summary Elpiscience Biopharma forms a $1.7 billion collaboration with Astellas Pharma to develop a bispecific macrophage engager. AstraZeneca acquires Gracell Biotech in a deal worth up to $1.2 billion, including a clinical stage CAR-T therapy. Jinan Qil...
2023-12-28 04:45:39 ET More on Astellas Pharma FDA approves Keytruda/Padcev combo therapy for bladder cancer Biden eyes seizing patents of taxpayer-funded drugs in bid to slash prices Seeking Alpha’s Quant Rating on Astellas Pharma ADR For further deta...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-15 18:20:05 ET More on Merck, Pfizer, etc. Pfizer: Dividend Boost At The Right Time Pfizer 2024 Guidance - Relentless COVID Pain Isn't Over Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Merck gets FDA approval for kidney cancer drug Welireg ...
2023-12-14 07:47:47 ET More on Apellis Pharma Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings C...
2023-12-08 04:54:49 ET More on Pfizer, Astellas Pharma Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Astella...
2023-12-06 11:19:36 ET Summary Apellis addressed Syfovre's safety issues, improving its situation; still, initial concerns about severe side effects remain relevant. Syfovre's market potential is significant as the first GA treatment, but rare vasculitis cases and competition pose...
2023-12-01 09:18:27 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earn...
2023-11-19 21:37:59 ET Summary Soros Fund Management's 13F portfolio value increased by 10% to $7.05B, with 209 positions. Top three individual stocks held were Horizon Therapeutics, Activision Blizzard, and Alphabet. New stakes included Activision Blizzard, Abcam plc, Novo No...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...